Informed Consent & Ethics Oversight
Every claim a clinical trial produces rests on a prior condition: that the people in it were there voluntarily, understood what they were agreeing to, and were protected by someone independent of the sponsor. Good Clinical Practice builds that protection from two structural safeguards — prospective review by an independent ethics committee, and an informed-consent process obtained before anything is done to the participant. They are not paperwork around the science; they are the thing that makes the science permissible, and they are the first place an inspection and a data reviewer both look.
What an explainer is not
A topic explainer is SPEQ’s synthesis of what a practice involves, cited to the standards that govern it. It does not reproduce their text, and it does not determine which of them apply to your product or process.
[ POSITION IN THE FRAMEWORK ]
7 DIMENSIONS · 22 LINKSInformed consent and ethics review are the two safeguards that make a trial permissible — a GCP and pharmacovigilance responsibility where consent is a process, not a signature, and a defect can invalidate a participant's dataset.
06 · QUALITY MATURITY — INFORMED CONSENT & ETHICS OVERSIGHT, REACTIVE TO ADAPTIVE
Consent is treated as a form to be signed; forms are collected under time pressure and ethics approval is chased after enrolment begins.
Consent SOPs and IRB/IEC submission exist, but version control of consent forms and re-consent triggers are handled inconsistently.
Consent is a documented process obtained before any trial procedure, forms are version-controlled to board approvals, and continuing review is tracked.
Consent and ethics status are monitored across sites so a lapsed approval or missed re-consent surfaces before it affects data usability.
Participant protection is designed in — vulnerable-population safeguards, board scrutiny of the consent process, and eConsent traceability are built into the trial.
SPEQ’s shared five-stage progression, labelled synthesis — not the FDA QMM rating scale. Where does your organization sit? Score your quality system →
07 · REGULATORY & EVIDENCE
GOVERNING STANDARDS · 4
Derived from the 4 standards SPEQ maps to this subject, across 3 regulatory bodies: ICH, FDA, EMA.
RECORDS & OBJECTIVE EVIDENCE
- Signed, dated informed-consent forms obtained before any trial-specific procedure
- Version-controlled consent forms mapped to IRB/IEC approvals
- IRB/IEC approval, amendment approval, and continuing-review correspondence
- Re-consent records where material new information emerged
- Additional-safeguard records for vulnerable participants (assent, legal representative)
COMMON INSPECTION FINDINGS
- Consent obtained after a screening or trial-specific procedure
- Participants enrolled under a consent-form version the board had not approved
- An amended protocol run before ethics approval of the amendment
- Continuing review lapsed during the trial
- Vulnerable-participant safeguards not in place or not documented
Consent is a process, not a form
The single most consequential misunderstanding in clinical research is that informed consent is a signed document. It is not — the document is only the record. Consent is a process: the participant must be given adequate information in language they understand, enough time and opportunity to consider it and ask questions, freedom from coercion or undue influence, and a genuine choice to decline or withdraw at any point without penalty. A perfectly completed form obtained under time pressure, or in a language the participant does not read, is not consent.
ICH E6(R3) and, in the United States, 21 CFR Part 50 set this out as an active obligation on the investigator. The signature and date matter because they must be contemporaneous — obtained *before* any trial-specific procedure begins. Consent taken after a screening blood draw is a finding, because the procedure preceded the permission. Re-consent is required whenever material new information emerges that could affect a participant’s willingness to continue.
Independent ethics review — the IRB/IEC
The second safeguard is structural: a trial may not begin until an independent Institutional Review Board or Ethics Committee has reviewed and approved the protocol, the consent materials, and the investigator’s suitability. In the US, 21 CFR Part 56 governs how these boards are constituted and operate; internationally the equivalent sits in ICH E6(R3) and, in the EU, in Regulation (EU) 536/2014. The board’s independence from the sponsor and investigator is the whole point — it exists to weigh participant welfare against the science on behalf of people who are not in the room.
The review is not one-and-done. The board approves before the trial, reviews substantial amendments before they take effect, is notified of safety issues, and conducts continuing review over the life of the trial. Running an amended protocol before the board has approved the amendment, or letting approval lapse, is a serious GCP finding regardless of whether any participant was harmed.
Vulnerable participants and the weight of the safeguards
Consent and ethics review flex according to how much protection a participant needs. Where participants may have limited capacity to consent — children, adults unable to consent for themselves, or situations of dependency — GCP requires additional safeguards: assent alongside a legally authorised representative’s permission, independent witnesses, and heightened board scrutiny. The principle is that the less able a person is to protect their own interests, the more the system must protect them.
This is also where the two safeguards reinforce each other. The ethics committee scrutinises the consent process precisely because vulnerability is where a consent form is most likely to be a formality rather than a genuine choice. GCP treats the design of the consent process for these populations as an ethics question the board must resolve, not a logistics question the site can settle alone.
Why inspectors start here
Consent and ethics documentation are the first things a GCP inspection examines, because a defect here can invalidate a participant’s entire dataset. A subject enrolled without valid consent, dosed before board approval, or kept on study through an unapproved amendment raises the question of whether their data can be used at all — which is why consent and ethics failures cascade into data-integrity and, ultimately, marketing-application problems.
The reusable rule mirrors the rest of GxP: the record must reconstruct the process. An inspector reads the consent forms, the version history, the dates against the procedure log, and the board’s approval and continuing-review correspondence, and asks a single question — can I prove that every participant consented, informed and in advance, under a protocol an independent board had approved? Everything the trial later claims depends on the answer being yes.
FREQUENTLY ASKED
Is informed consent a form or a process?
A process. The signed form is only the record of it. Valid consent requires adequate information in an understandable language, time to consider and ask questions, freedom from coercion, and a real choice to decline or withdraw — all before any trial-specific procedure begins. A completed form obtained under those conditions is evidence of consent; a form alone is not.
What is the difference between an IRB and an IEC?
They are the same safeguard under different names: an Institutional Review Board (IRB, the US term under 21 CFR Part 56) and an Independent Ethics Committee (IEC, the ICH/EU term) are independent bodies that must review and approve a trial’s protocol and consent materials before it starts, then provide continuing review. Their independence from the sponsor and investigator is the point.
When must informed consent be obtained?
Before any trial-specific procedure is performed on the participant — including screening procedures done only because of the study. Consent obtained after such a procedure is a GCP finding, because the procedure preceded the permission. Re-consent is required when material new information emerges that could affect willingness to continue.
Why do inspectors examine consent and ethics records first?
Because a defect there can invalidate a participant’s entire dataset. A subject enrolled without valid consent or dosed before ethics approval raises the question of whether their data can be used at all, so consent and ethics failures cascade into data-integrity and marketing-application problems.